肿瘤细胞治疗研究
英文原题：Accelerating Translation of NK Cell Therapies to the Clinic: A European Perspective.
Accelerating Translation of NK Cell Therapies to the Clinic: A European Perspective.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
过继性免疫治疗已成为治疗血液系统恶性肿瘤的一种有前景的策略。迄今为止，已有七种嵌合抗原受体（CAR）-T细胞产品在欧洲获得针对B细胞恶性肿瘤的上市许可，为符合条件的患者带来了治疗上的革命性变化。此外，由于自然杀伤（NK）细胞和T细胞具有强大的内在细胞毒性和良好的安全性特征，它们在细胞治疗领域尤其受到关注。应对NK细胞治疗临床转化所面临的挑战，是2026年3月11日至13日在德国弗赖堡举行的NK & ILC研讨会上讨论的问题之一，该研讨会是德国免疫学会（DGfI）NK & ILC研究组的年会。在为期3天的会议中，讨论议题从基础免疫学研究到技术创新和临床试验结果，涵盖40多场报告和100份壁报。会议的一个亮点是一场以简短报告和小组讨论为形式的工作坊，专门聚焦于NK细胞治疗临床实施当前面临的挑战和未来前景；本观点性论文对该工作坊的内容进行了总结。
Adoptive immunotherapies have emerged as a promising strategy in the treatment of hematological malignancies. To date, seven chimeric antigen receptor (CAR)-T cell products have obtained market authorization in Europe for B-cell malignancies, where they have revolutionized treatment for eligible patients.
In addition, natural killer (NK) cells and T cells are of particular interest for cell-based therapies due to their strong intrinsic cytotoxicity and favorable safety profile. Addressing challenges facing the clinical translation of NK cell therapies was one of the issues discussed in the NK & ILC Symposium that took place in Freiburg, Germany from March 11 to 13, 2026, as the annual meeting of the NK & ILC study group of the German Society for Immunology (DGfI).
Topics ranging from basic immunological research to technological innovations and clinical trial results were discussed during the 3-day conference, spanning over 40 presentations and 100 posters. A highlight of the conference was a workshop featuring short presentations and a panel discussion that focused specifically on the current challenges and future prospects of the clinical implementation of NK cell therapies; the findings of this workshop are summarized in this opinion paper.
MEMBER ACCOUNT
登录成功会直接打开下一页。
